Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors by Hynds, RE et al.
Short Report
Expansion of airway basal epithelial cells from primary
human non-small cell lung cancer tumors
Robert E. Hynds 1,2, Assma Ben Aissa3, Kate H.C. Gowers4, Thomas B.K. Watkins2, Leticia Bosshard-Carter1,4,
Andrew J. Rowan2, Selvaraju Veeriah1, Gareth A. Wilson2, Sergio A. Quezada3, Charles Swanton1,2,
on behalf of the TRACERx Consortium and Sam M. Janes4
1 UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, University College London, London, United Kingdom
2 Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, United Kingdom
3 Cancer Immunology Unit, UCL Cancer Institute, University College London, London, United Kingdom
4 Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom
Pre-clinical non-small cell lung cancer (NSCLC) models are poorly representative of the considerable inter- and intra-tumor het-
erogeneity of the disease in patients. Primary cell-based in vitro models of NSCLC are therefore desirable for novel therapy
development and personalized cancer medicine. Methods have been described to generate rapidly proliferating epithelial cell
cultures from multiple human epithelia using 3T3-J2 feeder cell culture in the presence of Y-27632, a RHO-associated protein
kinase (ROCK) inhibitor, in what are known as “conditional reprograming conditions” (CRC) or 3T31 Y. In some cancer studies,
variations of this methodology have allowed primary tumor cell expansion across a number of cancer types but other studies
have demonstrated the preferential expansion of normal epithelial cells from tumors in such conditions. Here, we report our
experience regarding the derivation of primary NSCLC cell cultures from 12 lung adenocarcinoma patients enrolled in the
Tracking Cancer Evolution through Therapy (TRACERx) clinical study and discuss these in the context of improving the success
rate for in vitro cultivation of cells from NSCLC tumors.
Introduction
Progress in normal epithelial biology has shown that the addi-
tion of a RHO-associated protein kinase (ROCK) inhibitor1,2 to
traditional keratinocyte growth medium and mitotically inacti-
vated 3T3-J2 murine embryonic feeder cell co-culture3 can
increase the number of cells expanded in vitro and help to
initiate cultures from small samples. Traditionally, the primary
culture of human cancer cells has been challenging, with few
tumors amenable to culture on plastic, so this protocol, known
as “conditional reprogramming” or “3T31Y,” has naturally
attracted attention in the cancer community. To date, variants
of this protocol have allowed cancer cell cultures to be
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established across multiple cancer types including lung, pros-
tate, pancreas and colon.4–6
In non-small cell lung cancer (NSCLC), a number of reports
demonstrate successful primary tumor cell culture using fibroblast
co-culture and ROCK inhibition.7–10 However, others have found
that normal epithelial cells are preferentially expanded in these
conditions.11,12 For example, Sette et al. recently showed strong
selection for normal, non-tumorigenic airway epithelial cells and/
or no tumor cell expansion from 19 surgically resected NSCLC
tumors of mixed histological subtypes, 4 pulmonary metastases, 2
lung cancer brain metastases and 1 patient-derived xenograft
(PDX) model.13
Here, we present cell culture outcomes for 12 lung adeno-
carcinoma patients enrolled in the on-going Tracking Cancer
Evolution through Therapy (TRACERx) clinical study.14,15 We
found that contaminating normal epithelial cells were the pre-
dominant cell type present in early passage cultures, although
tumor cells were cultured in one case. We discuss these find-
ings with a view to improving the efficacy of primary cell cul-
ture methodologies for early stage NSCLC tumors.
Materials and Methods
Cell culture
Ethical approval for generating patient-derived models was
obtained through the Tracking Cancer Evolution through
Therapy (TRACERx) clinical study (REC reference 13/LO/
1546). 3T3-J2 mouse embryonic fibroblast feeder cells were
cultured in DMEM (Invitrogen, UK) containing 1X penicil-
lin/streptomycin (Gibco, UK) and 9% bovine serum (Invitro-
gen). Feeder layers were prepared by inactivating confluent
3T3-J2 fibroblasts in medium containing 0.4 lg/ml mitomy-
cin C (Sigma Aldrich, UK) for 2 hr and re-plating these at
20,000 cell/cm2 in fibroblast growth medium. Feeder cells
were allowed to adhere overnight before tumor-derived cells
were added. Tumors were received on ice in transport
medium consisting of MEM alpha medium (Gibco) contain-
ing 1X penicillin/streptomycin (Gibco), 1X gentamicin
(Gibco) and 1X amphotericin B (Fisher Scientific, UK) after
fresh dissection. Tumors were digested to single cell suspen-
sions in serum-free RPMI medium (Gibco) containing 0.25
U/ml LiberaseTM (Roche, UK) and 0.1 mg/ml DNAse I
(Sigma) in a waterbath at 378C for 2 hr with regular agita-
tion. Tumor-derived cells were plated on 3T3-J2 feeder layers
in epithelial cell culture medium containing EGF and Y-27632
(3T31Y) as previously described.16,17 Airway spheroids, or
“tracheospheres,” were generated using a previously published
protocol.16
Histology
Samples were fixed in 4% PFA for 30 min at room temperature
(tracheospheres16) or overnight at 48C (subcutaneous tumors
and primary tissue) and processed for paraffin embedding
according to standard protocols. 4 lm formalin-fixed, paraffin-
embedded (FFPE) sections were hematoxylin and eosin (H&E)
stained using an automated tissue processor (Tissue-Tek, The
Netherlands). 403 images were acquired using a NanoZoomer
2.0HT whole slide imaging system (Hamamatsu Photonics,
Japan). For immunofluorescence, slides were dewaxed using an
automated protocol and antigen retrieval was performed using
citrate buffer (pH 6.0). Primary antibodies were anti-MUC5B
(Sigma HPA008246), anti-ACT (Sigma T6793) and anti-p63
(Abcam, UK, ab53039). Species-appropriate secondary anti-
bodies were conjugated to Alexa Fluor dyes (Molecular Probes,
UK; 1:500). Images were acquired using a Zeiss LSM700 confo-
cal microscope.
Immunocytochemistry
Culture-expanded cells were seeded into 8-well, collagen-coated
chamber slides (Ibidi, Germany) with feeder cells and expanded
for 4 days. Cells were washed with PBS and fixed with 4% PFA
at room temperature for 30 min. Cells were stored at 48C in PBS
until staining. Cells were permeabilized and blocked for 1 hr in
PBS containing 10% FBS and 0.01% Triton X-100 (Fisher Scien-
tific). Primary antibodies were anti-pan-keratin (Dako, USA,
M3515; 1:500), anti-keratin 5 (Abcam ab52635; 1:200), anti-p63
(Abcam ab124762; 1:300) and anti-TTF-1 (Abcam ab76013;
1:200). These were incubated overnight at 48C in block buffer
without Triton X-100. Cells were washed three times with PBS
before addition of species-appropriate secondary antibodies
(Alexa Fluor; Molecular Probes; 1:500) at room temperature for
2 hr in block buffer without Triton X-100.
Subcutaneous xenografts
Animal studies were approved by the University College London
Biological Services Ethical Review Committee and licensed under
UK Home Office regulations. Six to eight week-old male immu-
nocompromised NOD/SCID/gamma (NSG) mice were pur-
chased from Charles River, kept in individually ventilated cages
What’s new?
Traditionally, the primary culture of human cancer cells has been challenging. A new protocol known as 3T31 Y has allowed
cancer cell cultures to be established across multiple cancer types, but reports are inconsistent for non-small cell lung cancer
(NSCLC). Here, the authors sought to expand tumor cells from surgically resected primary human lung adenocarcinoma tumors
within the TRACERx clinical study using 3T31 Y. Contaminating normal epithelial cells were the predominant cell type in early
passage cultures, although KRAS-mutant tumor cells were cultured in one donor culture. The researchers urge caution in the
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under specific pathogen-free conditions and had ad libitum
access to both sterile food and autoclaved water. To generate
subcutaneous tumors, mice were anaesthetized using 2–4%
isoflurane, the right flank was shaved and cleaned before 200
ll growth-factor reduced Matrigel containing 1 3 106 cultured
cells was injected subcutaneously. Animals were observed during
recovery, then regularly monitored for tumor growth. Experi-
ments lasted for 3 months or were terminated before tumors
reached 1.5 cm3 in volume.
Next-generation sequencing (NGS)
NGS of a TruSeq custom amplicon for lung cancer panel that
comprises 107 hotspot amplicons from 15 genes was performed
using the MiSeq system (Illumina). The NGS amplicon library
preparation was performed using 125 ng DNA as input for
patient tissue and cell cultures derived from patient-matched
tumors. The resulting sequence library was normalized and
pooled prior to sequencing on a MiSeq instrument according to
the manufacturer’s instructions (Illumina, USA). We used a
MiSeq Reagent Kit v2 (300 cycles) with 2 3 150 paired-end
sequencing design according to the manufacturer’s instructions
(Illumina). The human hg19 genome assembly was used to
align the paired-end raw reads.
The variant allele frequencies of 24 SNPs previously identi-
fied by Pengelly et al.18 were extracted for each sequenced cell
culture and compared to previously sequenced tumor regions
from the same patient to confirm that no sample swaps had
occurred between patients.
SAMtools mpileup19 (0.1.19; base phred score >20 and read
mapping quality >20, BAQ computation disabled), Varscan220
(v2.4.1; includes running fpfilter.pl) and MuTect21 (v1.1.7)
were used to locate non-reference positions in cell culture,
tumor and germline samples. To reduce false positive variant
calls, additional filtering was performed. A variant allele fre-
quency of 5% was required with somatic p-values <50.01,
sequencing depth in each region was required to be >530 and
>510 sequence reads had to support the variant call. In con-
trast, the VAF in the germline data had to be <51% whilst the
number of reads supporting the variant had to be <5. Finally,
variants designated as “germline” by VarScan2 from all regions
in all 100 patients within the TRACERx exome cohort14 were
combined so that every germline variant detected in the cohort
had an associated TRACERx population frequency. SNVs were
filtered if they were found to have >1% frequency in the
TRACERx germline cohort.
Results
We attempted cell culture from 12 patients (median age5 75
years, range5 58–90 years), whose surgically resected primary
lung adenocarcinoma (LUAD) tumors (stage II [n5 9] or III
[n5 3]) are being analyzed in the on-going Tracking Cancer
Evolution through Therapy (TRACERx) clinical study,14,15
using a published protocol.17 We obtained primary epithelial
cell cultures that could be passaged from 10 (83.3%) of these.
Tumor-derived cells were morphologically indistinguishable
from normal human airway epithelial cells in 3T31Y culture
and expressed proteins associated with airway basal cells, such
as keratin 5 and the transcription factor p63 (Fig. 1a). The
LUAD-associated protein TTF-1 (also known as homeobox
protein NKX-2.1) was expressed by cultured cells (Fig. 1a; 3/3)
but is also expressed by normal airway basal cells. To morpho-
logically distinguish contaminating basal cells from tumor cells,
we grew four of the cell cultures in 3D differentiation condi-
tions,16 expecting that cells would form either hollow normal
airway “tracheospheres” or solid tumor spheroids.22 Cells
underwent lumen formation and generated epithelial spheroids
containing differentiated airway epithelial cell types, suggesting
that we had expanded normal airway basal cells from these
tumors (Fig. 1b; 4/4).
To further examine whether we had expanded cancer cells
or normal epithelial cells, we subcutaneously injected 1 3 106
culture-expanded cells in 100% growth factor-reduced Matrigel
in immunocompromised (NSG) mice. After 3 months, no
tumors developed in mice injected with tumor-derived epithe-
lial cell cultures (0/3). In Matrigel retrieved from these mice, we
found epithelial cells with the characteristics of differentiated
normal human proximal airway epithelial cells (Fig. 1c).
The preferential expansion of normal human airway basal
cells in these conditions was subsequently confirmed using
sequencing approaches. The primary patient tumors had
undergone next-generation sequencing (NGS) of a targeted
panel of SNVs in 15 lung cancer-associated genes and amplifi-
cations in a further 3 genes using the Illumina MiSeq system
within the TRACERx study. Equivalent NGS of the ten patient-
matched early passage cell cultures confirmed that cancer
mutations were not detected in nine of ten cultures (!5 pas-
sages; Fig. 1d). Since p631 cells can be found within LUAD
tumors (Fig. 1e), it is likely to be these cells that are expanded
in culture. However, in one passage 2 cell culture that was not
investigated in prior assays, we detected all three mutations
that were found in the patient’s tumor at high variant allele fre-
quencies by MiSeq (81.3% mutant KRAS; Fig. 1d) and these
cells gave rise to a tumor on subcutaneous injection in an NSG
mouse (Fig. 2). Cells could be re-cultured in 3T31Y following
recovery of the xenograft tumor and Sanger sequencing dem-
onstrated that these were KRAS mutant (Fig. 2). Interestingly,
Sanger sequencing of the parent cell culture just two passages
later (i.e., passage 4) did not detect mutant KRAS (Fig. 2),
suggesting that normal epithelial cells rapidly out-grow cancer
cells in this culture system when both are present.
Overall, these data show that 3T31Y conditions sup-
ported tumor cell expansion for just 1 of 10 NSCLC tumors
and that selection of cancer cells over normal epithelial cells
is essential for cancer cell culture maintenance.
Discussion
Our results suggest that a very small number of contaminat-
ing normal airway basal cells contained within LUAD tumors
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corroborating the recent findings of Sette et al.13 and
others.11,12 Even after careful dissection of tissue by a pathol-
ogist to obtain normal lung and tumor samples, bronchioles
containing normal airway epithelium can be found in the
NSCLC tumor microenvironment (Fig. 1e).
It has been possible to establish cultures of tumor
mutation-bearing cells in many NSCLC cases,8,9,23 including
from PDX tumors,24 but the widespread utility of the
“conditional reprogramming” method still remains to be
established, particularly in early stage disease and from tumor
samples derived from surgical resection or autopsy. Studies
that report normal epithelial cell expansion have tended to
initiate culture from early-stage primary NSCLC tumors,
whereas studies in which cancer cells have been expanded
have initiated culture using biopsies or effusions from
patients with late-stage, therapy-resistant disease7–9 or from
PDX models,24 which may be more aggressive and/or more
adaptable to cell culture. This would be consistent with tradi-
tional NSCLC cell culture methods and PDX models, where
patient models are more readily established from late-stage,
metastatic or therapy-resistant disease than from early-stage
primary disease. As well as disease stage, tumor genotype
could also be an important determinant of culture success in
these conditions: previous studies focus on biopsies and
Figure 1. Frequent expansion of normal human airway epithelial cells from non-small cell lung cancer (NSCLC) tumors in 3T3-J2 co-culture
in the presence of Y-27632 (3T31 Y). (a) Immunofluorescence staining for pan-keratin, keratin 5, p63 and TTF-1 in a representative culture
(n53 patients; scale bar5100 lm). (b) In vitro tracheosphere assay. Hematoxylin and eosin (H&E) staining (top panel, scale bar51 mm;
bottom left panel, scale bar550 lm) demonstrated airway differentiation capacity of cell cultures expanded from NSCLC tumors (<passage
5; representative images, n54 patients). Immunofluorescence confirmed the presence of ACT1 ciliated cells and MUC5B1 mucosecretory
cells (bottom right panel, scale bar550 lm). (c) Subcutaneous injection tumorigenesis model. Injection of cultured cells (<passage 5) into
NSG mice did not lead to tumor formation but H&E analysis showed the presence of epithelium resembling that found in human airways
after 3 months (3/3 patients; top panel scale bar5500 lm; middle panel scale bar550 lm). Immunofluorescence confirmed the presence
of ACT1 ciliated cells and MUC5B1 mucosecretory cells (bottom panel, scale bar550 lm). (d) Next-generation sequencing using the Illu-
mina MiSeq platform did not detect mutations found in the tumor of origin in 9/10 NSCLC cell cultures. “Multiple” indicates that more
than one variant results from the specific mutation detected, i.e., it affects multiple isoforms at different positions. (e) H&E analysis showed
bronchiolar epithelium within a human lung adenocarcinoma tumor (left panel, scale bar51 mm; top right panel, scale bar5100 lm).
Immunofluorescence confirmed the presence of p631 basal epithelial cells within these bronchioles (bottom right panel, scale bar550
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Figure 2. Expansion of primary human tumor cells from a KRAS-mutant lung adenocarcinoma in 3T3-J2 co-culture in the presence of Y-27632
(3T31 Y). Cancer mutation-bearing cells were detected in 1 of our 10 early passage patient cultures (CRUK0557) by next-generation sequenc-
ing. Sanger sequencing of the same cell culture at later passage (P4; scale bar5100 lm) revealed that the KRAS mutation was no longer
detected (left panel). Injection of the early passage (P2) cell culture into an immune-compromised (NSG) mouse generated a tumor with mutant
KRAS (center panel). A hematoxylin and eosin (H&E)-stained section is shown (scale bar5500 lm). A magnified view of the black dotted box
is shown below (scale bar5100 lm). Re-culture of cells from the cell culture-derived xenograft in 3T31Y was possible (right panel; scale















plural effusions from EGFR-mutant/ALK-positive tumors,
while 7 of our 10 LUAD tumors were driven by mutant
KRAS.
Despite containing less tissue, biopsies or pleural effusion
samples might also be advantageous for initiating tumor cul-
tures by virtue of their lack of contaminating normal epithe-
lium9 as normal epithelial cells outgrow patient-matched
cancer cells in controlled 3T31Y experiments.11 Normal
cells also outcompete tumor-derived cells during cancer orga-
noid derivation. Here, it has been possible to develop tumor-
specific media to select tumor organoids over normal
colonic25 and hepatic26 epithelial organoids. For example,
intestinal epithelial cells are dependent on exogenous Wnt in
culture but constitutively active Wnt signaling, due to geno-
mic aberrations in genes such as APC and/or CTNNB1, often
confers tumor cells with the ability to survive culture in
Wnt-free culture media. Such strategies might be relevant in
NSCLC culture: for example, EGF could be withdrawn in
cases where tumors have EGFR-activating mutations or
nutlin-3 could be added to P53-mutant tumor cultures.25
These selection strategies could be effective in cases where
the tumor genotype is known at the time of surgery or in
lung squamous cell carcinoma cell culture where the vast
majority of tumors are P53 mutant. While the current data
suggest LUAD tumor cells are lost very early during culture
in 3T31Y, it remains possible that normal cells actively
limit tumor cell expansion and selection might permit the
growth of tumor cells.
Protocol optimization is clearly required to adapt recent
progress in epithelial biology towards routine utility in cancer
studies. Protocol differences exist between the aforemen-
tioned studies: key studies have used inactivated human der-
mal fibroblasts7,8 as feeder layers rather than the mouse
embryonic fibroblasts often used in those that see normal cell
expansion and it has also been possible to transition tumor
cell cultures off feeder layers after 6 months of culture estab-
lishment.8 We have previously demonstrated that adult
human lung fibroblasts do not support long-term normal air-
way epithelial cell expansion in the same way as 3T3-J2
cells17 so the use of adult and/or human feeder cells might
favor tumor cell expansion. Relevant biological differences
might also exist between mitotic inactivation using irradia-
tion4,9 rather than mitomycin C, as used here. Alternatively,
different tissue acquisition methods,9 feeder cell-conditioned
medium,10,27 low oxygen,10 harsh tissue digestion protocols26
and/or initially serum-starving cells6 might help to select
tumor cells by inducing differentiation or apoptosis in nor-
mal epithelial cells.
In summary, researchers should remain cautious in their
use of NSCLC primary cell cultures, particularly from early-
stage tumors; genomic analyses should confirm the tumor
origin of individual cultures and, if present, the proportion of
tumor cells should not be assumed to be consistent over pas-
sage.23 While 3T31Y culture conditions have clear applica-
tions in disease modeling in respiratory conditions with
airway epithelial involvement, further work is required to
realize its applications in modeling human cancer and in the
development of personalized cancer therapies.
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